- LivTech Inc. and Yakult Honsha Co.,Ltd. entered into an Option Agreement for LIV-2008 Project
LivTech translates cutting-edge cancer stem cell research in Japan into the discovery and development of therapeutic antibodies targeting malignant tumors. It has developed a unique research platform that targets carcinogenesis and has a pipeline of lead candidates with significant anti-cancer activity. LivTech is committed to the delivery of new antibody therapeutics to eliminate cancer, and dream of contributing to the health and wellbeing of the wider society.